BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. The Company is scheduled to present on Thursday, January 16, 2020, at 11:00 a.m. PT.
Karuna recently announced that KarXT met its primary endpoint in the Phase 2 clinical trial studying KarXT in acute psychosis in patients with schizophrenia. The company will discuss these results and other business updates during its presentation.
A live webcast of the presentation will also be available on the investor relations page of the Karuna corporate website at investors.karunatx.com. After the live webcast, the event will remain archived on the Karuna website for 30 days.
Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.